Research Topics
Genomes and Genes | T Mark DohertySummaryAffiliation: Statens Serum Institut Country: Denmark Publications
| Collaborators
|
Detail Information
Publications
Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosisAbebech Demissie
Armauer Hansen Research Institute, Addis Ababa, Ethiopia
Clin Vaccine Immunol 13:179-86. 2006....- Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patientsT Mark Doherty
Department of Tuberculosis Immunology, Statens Serum Institute Hvidovre Hospital, Copenhagen, Denmark
J Clin Microbiol 40:704-6. 2002..We report that strong recognition of tuberculosis complex-specific antigen ESAT-6 by healthy household contacts of tuberculosis patients correlates with the subsequent development of active tuberculosis during a 2-year follow-up period... 
Biomarkers for tuberculosis disease status and diagnosisMark Doherty
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
Curr Opin Pulm Med 15:181-7. 2009..As a result, recent years have seen the initiation of large-scale studies aiming to identify biomarkers of Mycobacterium tuberculosis infection and disease. This review discusses initial results and future prospects for that work...- Tuberculosis subunit vaccines: from basic science to clinical testingT Mark Doherty
Statens Serum Institute, Department of Infectious Disease Immunology, Copenhagen, Denmark
Expert Opin Biol Ther 7:1539-49. 2007..The challenges that confront these approaches and how they are being addressed are then discussed... - Vaccines for tuberculosis: novel concepts and recent progressT Mark Doherty
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
Clin Microbiol Rev 18:687-702. 2005..This provides a background for describing the new generation of vaccines designed to supplement or replace the current vaccine and the different approaches they take to stimulate immunity against M. tuberculosis... 
Biomarkers of disease activity, cure, and relapse in tuberculosisT Mark Doherty
Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, 2300 København S, Denmark
Clin Chest Med 30:783-96, x. 2009..As a result, research aiming to identify biomarkers of Mycobacterium tuberculosis infection and disease has flourished. This article discusses the most recent findings of that work...- Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCRT Mark Doherty
Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark
J Immunol Methods 298:129-41. 2005..Researchers should carefully consider these factors when planning human field studies... - Real world TB vaccines: clinical trials in TB-endemic regionsT Mark Doherty
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
Vaccine 23:2109-14. 2005..tuberculosis infection is expanding rapidly. This review summarizes the developing consensus on the BCG vaccine and its limitations and discusses clinical trials of some of the new vaccines intended to supplement or replace it... - Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosisT Mark Doherty
Department of Infectious Disease Immunology, Statens Seruminstitut, Copenhagen, Denmark
J Infect Dis 190:2146-53. 2004.... - Tuberculosis vaccine developmentT Mark Doherty
Department of Tuberculosis Immunology, Statens Serum Institut, Copenhagen, Denmark
Curr Opin Pulm Med 8:183-7. 2002..This selection is being eased by the improved animal models that have been developed over the past few years and by our increasing understanding of immunity to TB... - New vaccines against tuberculosisT Mark Doherty
Department of TB Immunology, Statens Serum Institute, Copenhagen, Denmark
Trop Med Int Health 9:818-26. 2004..This review summarizes recent advances in tuberculosis vaccine development, with a special emphasis on issues raised at the Gorée meeting about testing and deploying new generation vaccines in TB-endemic areas such as Africa... - Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunityJes Dietrich
Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, DK 2300 Copenhagen, Denmark
J Immunol 177:6353-60. 2006..tb in LTK63/Ag85B-ESAT-6-boosted mice, compared with BCG-vaccinated animals. Thus, LTK63/Ag85B-ESAT-6 represents an efficient preventive vaccine against tuberculosis with a strong ability to boost prior BCG immunity... - Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosisThomas Bennekov
Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
Eur J Immunol 36:3346-55. 2006.... - Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosisT Mark Doherty
Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark
Infect Immun 70:3111-21. 2002.... - Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacyJes Dietrich
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
J Immunol 174:6332-9. 2005..4, we show that ESAT-6, apart from being an excellent diagnostic reagent, can also be used as a reagent for monitoring vaccine efficacy. This may open a new way for monitoring vaccine efficacy in clinical trials... - The prognosis of latent tuberculosis: can disease be predicted?Peter Andersen
Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej 5, DK 2300 Copenhagen S, Denmark
Trends Mol Med 13:175-82. 2007..This might provide an unprecedented advantage for TB control, namely targeted preventive therapy for individuals who are most at risk of developing active contagious TB... - Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protectionJes Dietrich
Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, Copenhagen, Denmark
J Immunol 178:3721-30. 2007..Thus, these studies suggest an immunization strategy where a novel TB subunit vaccine is administered as part of the child vaccination program together with BCG in neonates and followed by subunit boosting... - Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine developmentJes Dietrich
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
APMIS 117:440-57. 2009..In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies... - Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigensKarin Weldingh
Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, DK 2300 Copenhagen S, Denmark
J Clin Microbiol 43:57-65. 2005..3 and the TB9.7 antigens were recognized by more than 85% of the samples from TB patients coinfected with human immunodeficiency virus, a patient group for which it is in general difficult to detect M. tuberculosis-specific antibodies... - The success and failure of BCG - implications for a novel tuberculosis vaccinePeter Andersen
Statens Serum Institute, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark
Nat Rev Microbiol 3:656-62. 2005..Here, we discuss the potential mechanisms behind the variation of BCG efficacy and their implications for an improved TB vaccination strategy... - TB subunit vaccines--putting the pieces togetherPeter Andersen
Department of Infectious Disease Immunology, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen, Denmark
Microbes Infect 7:911-21. 2005..This requires carefully monitoring aspects as immunodominance, recognition in different populations as well as vaccine manufacturing... - Progress and hindrances in tuberculosis vaccine developmentT Mark Doherty
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
Lancet 367:947-9. 2006 - Evaluation of Mycobacterium tuberculosis--specific antibody responses in populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and DenmarkSoren T Hoff
Department of Infectious Diseases Immunology, Statens Serum Institute, Copenhagen S, Denmark
Clin Infect Dis 45:575-82. 2007..A key question remaining is the extent to which the disappointing performance of current tests is associated with a high background prevalence of latent TB... - Selecting the components for a safe and efficient tuberculosis subunit vaccine--recent progress and post-genomic insightsLimei Meng Okkels
Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
Curr Pharm Biotechnol 4:69-83. 2003..In this review, we discuss how these new approaches have accelerated the pace of antigen discovery and vaccine development, and highlight some of the most promising new candidate vaccines and vaccine targets... - Vaccines in a hurryChristian Søborg
Statens Serum Institut, Copenhagen, Denmark
Vaccine 27:3295-8. 2009.... - TB vaccines: current status and future perspectivesClaus Aagaard
Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
Immunol Cell Biol 87:279-86. 2009..Three such fusion proteins are currently in clinical trials, the two most advanced have already passed phase I trials and are entering phase II... 
Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosisJean Michel Hougardy
Laboratory of Vaccinology and Mucosal Immunity, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium
PLoS ONE 2:e926. 2007..We have therefore evaluated the potential of the novel antigen heparin-binding hemagglutinin (HBHA) for in vitro detection of LTBI...- Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over timeLiya Wassie
Armauer Hansen Research Institute, Addis Ababa, Ethiopia
PLoS ONE 3:e1522. 2008.... - The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferonAbebech Demissie
Armauer Hansen Research Institute, Addis Ababa, Ethiopia
Infect Immun 74:2817-22. 2006.... - The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infectionClaudia Rolinck-Werninghaus
Eur J Pediatr 162:534-6. 2003 - Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6Jan A M Langermans
Department of Parasitology, Biomedical Primate Research Centre, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands
Vaccine 23:2740-50. 2005..As far as we are aware this is the first report of protection in primates with a subunit vaccine... - Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2Abebech Demissie
Armauer Hansen Research Institute, Addis Ababa, Ethiopia
J Immunol 172:6938-43. 2004..These data suggest that long-term control of M. tuberculosis infection is associated not just with elevated Th1 responses but also with inhibition of the Th2 response... - Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosisAnn Williams
Health Protection Agency, Porton Down, Salisbury SP4 OJG, UK
Tuberculosis (Edinb) 85:29-38. 2005..A relatively high aerosol-challenge dose and evaluation over a protracted time post-challenge allowed superior protection over BCG to be demonstrated by BCG boosted with MVA and fowl pox vectors expressing Ag85A... - Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulationHelen A Fletcher
The Centre for Infectious Diseases and International Health, Windeyer Institute of Medical Sciences, Royal Free and University College Medical School, London, UK
Immunology 112:669-73. 2004..tuberculosis induces unusual, previously unrecognized, immunological events. We tentatively hypothesize that progression to active disease might depend upon the underlying ratio of IL-4 to IL-4delta2... - Mycobacterium avium complex promotes recruitment of monocyte hosts for HIV-1 and bacteriaHollie Hale-Donze
Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, and Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 169:3854-62. 2002..In vivo, opportunistic infection may act as a recruitment mechanism in which newly arrived monocytes serve as naive hosts for both MAC and HIV-1, thus perpetuating both infections...